KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Payables (2016 - 2025)

Charles River Laboratories International (CRL) has 17 years of Payables data on record, last reported at $148.8 million in Q4 2025.

  • For Q4 2025, Payables rose 6.03% year-over-year to $148.8 million; the TTM value through Dec 2025 reached $148.8 million, up 6.03%, while the annual FY2025 figure was $148.8 million, 6.03% up from the prior year.
  • Payables reached $148.8 million in Q4 2025 per CRL's latest filing, down from $169.6 million in the prior quarter.
  • Across five years, Payables topped out at $226.0 million in Q1 2022 and bottomed at $110.9 million in Q2 2021.
  • Average Payables over 5 years is $155.4 million, with a median of $143.1 million recorded in 2024.
  • Peak YoY movement for Payables: skyrocketed 90.56% in 2022, then crashed 46.9% in 2023.
  • A 5-year view of Payables shows it stood at $198.1 million in 2021, then grew by 3.93% to $205.9 million in 2022, then dropped by 17.96% to $168.9 million in 2023, then dropped by 16.93% to $140.3 million in 2024, then rose by 6.03% to $148.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $148.8 million in Q4 2025, $169.6 million in Q3 2025, and $145.8 million in Q2 2025.